Ultragenyx shares plunge after apazunersen Phase 3 misses endpoints
Ultragenyx Pharmaceutical’s shares fell after Phase 3 apazunersen for Angelman missed key endpoints, triggering a program review and cost cuts. Positive GENGLYCOS data and upcoming UX111 and gene-therapy readouts keep focus on the pipeline.